iBio, Inc. (NYSE:IBIO – Get Free Report) Director David Arkowitz purchased 18,382 shares of the firm’s stock in a transaction on Friday, January 10th. The shares were acquired at an average price of $2.72 per share, with a total value of $49,999.04. Following the completion of the acquisition, the director now owns 18,382 shares in the company, valued at approximately $49,999.04. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.
iBio Stock Down 2.7 %
Shares of iBio stock opened at $2.48 on Tuesday. The company has a current ratio of 3.37, a quick ratio of 3.37 and a debt-to-equity ratio of 0.04. The business has a 50-day moving average price of $2.51 and a two-hundred day moving average price of $2.29. iBio, Inc. has a 1-year low of $1.02 and a 1-year high of $4.98.
iBio (NYSE:IBIO – Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.46) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.46). As a group, sell-side analysts expect that iBio, Inc. will post -1.74 earnings per share for the current year.
About iBio
iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.
Further Reading
- Five stocks we like better than iBio
- Learn Technical Analysis Skills to Master the Stock Market
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- 10 Best Airline Stocks to Buy
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- There Are Different Types of Stock To Invest In
- Delta Can Fly to New Highs in 2025; Here’s Why
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.